JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

NCT06079983 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: JSKN003
DRUG: Capecitabine tablets
DRUG: Gemcitabine hydrochloride for injection
DRUG: Vinorelbine tartrate injection
DRUG: Paclitaxel for injection (albumin-bound type)
DRUG: Docetaxel injection
DRUG: Eribulin mesylate injection

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd